Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL -3.80%66 EV-to-EBITDA is 228.85 as of Aug. 30, 2026, which is 697% above its 10-year median of 28.72. GuruFocus rates ZJYL with a GF Score™ of 66/100 and a GF Value™ of $12.85 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 520 Medical Devices & Instruments companies, Jin Medical International ranks worse than 97.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jin Medical International's enterprise value is $166.84 Mil.
Jin Medical International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.73 Mil. Therefore, Jin Medical International's EV-to-EBITDA for today is 228.85.
The historical rank and industry rank for Jin Medical International's EV-to-EBITDA or its related term are showing as below:
ZJYL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.85 Med: 28.72 Max: 610.7
Current: 228.85
During the past 6 years, the highest EV-to-EBITDA of Jin Medical International was 610.70. The lowest was 3.85. And the median was 28.72.
ZJYL's EV-to-EBITDA is ranked worse than 97.88% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 14.66
vs ZJYL: 228.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Jin Medical International (NAS:ZJYL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jin Medical International's PE Ratio (TTM) for today is calculated as:
Jin Medical International's share price for today is $2.36.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jin Medical International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Jin Medical International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jin Medical International's EV-to-EBITDA falls into.
Jin Medical International's current Enterprise Value is $166.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jin Medical International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International (ZJYL) has a EV-to-EBITDA of 228.85 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jin Medical International. This is 697% above median its historical median of 28.72. Over the past decade, Jin Medical International's EV-to-EBITDA has ranged from 3.85 to 610.70. According to the industry distribution chart, Jin Medical International ranks #509 out of 520 companies in the Medical Devices & Instruments industry, placing it in the top 97.9%.
Is Jin Medical International's EV-to-EBITDA too high?
Jin Medical International's current EV-to-EBITDA of 228.85 is 697% above median its 10-year median of 28.72. Over the past 10 years, this metric has ranged from a low of 3.85 to a high of 610.70. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.66. Jin Medical International's value of 228.85 is 1461.1% above this industry median. Based on the distribution chart, Jin Medical International ranks #509 out of 520 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Jin Medical International has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's EV-to-EBITDA compare to RGNT and BNGO?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #509 out of 520 companies for EV-to-EBITDA. This places Jin Medical International in the lower half of its industry. The industry median EV-to-EBITDA is 14.66. Jin Medical International's value of 228.85 is 1461.1% above this benchmark. Historically, Jin Medical International's own EV-to-EBITDA has ranged from 3.85 to 610.70 over the past decade. While the company's 10-year median is 28.72 vs. the industry median of 14.66, Jin Medical International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.66, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current EV-to-EBITDA of 228.85 is 1461.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jin Medical International. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current EV-to-EBITDA is 228.85, which is 697% above median its own 10-year median of 28.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.85, compared to a current price of $2.36 — trading 81.6% below its estimated fair value. The current EV-to-EBITDA is 228.85, which is 697% above median its 10-year median of 28.72 and 1461.1% above the Medical Devices & Instruments industry median of 14.66. Jin Medical International's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current EV-to-EBITDA is 228.85 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $2.36 is trading 81.6% below its estimated GF Value™ of $12.85.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
EV-to-EBITDA: 228.85 (697% above median its 10-year median of 28.72)
GF Value™: $12.85 vs. price of $2.36 (81.6% below fair value)
Industry Position: 1461.1% above the Medical Devices & Instruments median (#509 of 520)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
66GF Score
Get the complete analysis for ZJYL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
